Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial
Authors:
- Kyle A. ArsenaultKAKyle A. Arsenault
- Jeremy S. PaikinJPJeremy S. Paikin
- Jack HirshJHJack Hirsh
- Brian DaleBDBrian Dale
- Richard P. WhitlockRWRichard P. Whitlock
- Kevin TeohKTKevin Teoh
- Ed YoungEYEd Young
- Jeffrey S. GinsbergJGJeffrey S. Ginsberg
- Jeffrey I. WeitzJWJeffrey I. Weitz
- John W. EikelboomJEJohn W. Eikelboom
- 1 October 2012
- journal article
- research article
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 144 (4) , 944-950.e3
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Heparin Brand Is Associated With Postsurgical Outcomes in Children Undergoing Cardiac SurgeryThe Annals of Thoracic Surgery, 2012
- Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?The Journal of Thoracic and Cardiovascular Surgery, 2004
- Anticoagulation Monitoring during Cardiac SurgeryAnesthesiology, 1999
- Do Different Heparin Brands Influence Activated Clotting Times?The Journal of ExtraCorporeal Technology, 1998
- The impact of heparin concentration and activated clotting time monitoring on blood conservationThe Journal of Thoracic and Cardiovascular Surgery, 1995
- Comparison of two protocols for heparin neutralization by protamine after cardiopulmonary bypassThe Journal of Thoracic and Cardiovascular Surgery, 1987
- Heparin therapy during extracorporeal circulationThe Journal of Thoracic and Cardiovascular Surgery, 1975
- Heparin therapy during extracorporeal circulationThe Journal of Thoracic and Cardiovascular Surgery, 1975
- The Platelet Aggregating Effect of Eight Commercial HeparinsScandinavian Journal of Haematology, 1972